Following engagement of the T cell antigen receptor (TCR) and formation of the immunological synapse, calcium (Ca 2+ ) channels mediate the Ca 2+ influx necessary for the activation of T cells 1 . Ca 2+ influx from the extracellular milieu into the cytosol is mandatory for the activation of downstream TCR signaling pathways and key transcription factors, including NFAT and NF-κB 2 . Ligation of the TCR triggers phosphorylation events that lead to activation of the Ca 2+ releaseactivated Ca 2+ channel complex and to store-operated Ca 2+ entry 3 . However, this canonical scheme of Ca 2+ influx does not account for the involvement of other plasma-membrane Ca 2+ channels.
Following engagement of the T cell antigen receptor (TCR) and formation of the immunological synapse, calcium (Ca 2+ ) channels mediate the Ca 2+ influx necessary for the activation of T cells 1 . Ca 2+ influx from the extracellular milieu into the cytosol is mandatory for the activation of downstream TCR signaling pathways and key transcription factors, including NFAT and NF-κB 2 . Ligation of the TCR triggers phosphorylation events that lead to activation of the Ca 2+ releaseactivated Ca 2+ channel complex and to store-operated Ca 2+ entry 3 . However, this canonical scheme of Ca 2+ influx does not account for the involvement of other plasma-membrane Ca 2+ channels.
Studies have documented the important contributions of voltagegated Ca 2+ channels 4, 5 and members of the transient receptor potential (TRP) family of ion channels 6, 7 to T cell activation. The mammalian TRP family of ion channels consists of 28 members categorized into six subfamilies: canonical (TRPC), with seven members; vanilloid (TRPV), with six members; melastatin (TRPM), with eight members; ankyrin (TRPA), with one member; polycystin (TRPP), with three members; and mucolipin (TRPML), with two members 8 . Although physiological roles of TRP channels are well characterized in the nervous system, their role in the activation and function of T cells is still elusive 2, 5, 6 .
The 'founding member' of the TRPV subfamily, TRPV1, is highly permeable to Ca 2+ (with a permeability to calcium relative to permeability to sodium (P Ca/ P Na ) of ~10) 9 and was initially identified as the receptor for capsaicin, the pungent ingredient in chili peppers 10 . In this study, we found that mouse and human primary CD4 + T cells expressed a functional TRPV1 channel (called 'TRPV1 CD4 ' here). We found that TRPV1 CD4 contributed to TCR-induced Ca 2+ influx and was required for proper downstream TCR signaling. Our data indicate a cell-intrinsic role for the TRPV1 channel in the activation of and acquisition of proinflammatory properties by CD4 + T cells.
RESULTS

Expression of functional TRPV1 by CD4 + T cells
We first compared the expression of mRNA encoding various TRP channels in primary CD4 + T cells isolated from the spleen of C57BL/6 (wild-type) mice. Among mRNA encoding the eight different TRP channels analyzed, Trpv1 transcripts had the highest expression (Fig. 1a) . We used CD4 + T cells isolated from Trpv1 −/− mice as a control (Fig. 1b) . We confirmed expression of TRPV1 protein in mouse spleen CD4 + T cells by flow cytometry (Fig. 1c) as well as in human primary CD4 + T cells and in the Jurkat human T lymphocyte cell line by immunoblot analysis (Supplementary Fig. 1a) . Confocal microscopy showed expression of TRPV1 predominantly at the plasma membrane of resting CD4 + T cells ( Fig. 1d and Supplementary Fig. 1b,c) . Indeed, the fluorescence signals of TRPV1 and CD4 were largely colocalized (Pearson's correlation coefficient, 0.96) (Fig. 1e) . Furthermore, cell-surface biotinylation assays confirmed localization of TRPV1 at the plasma membrane of Jurkat T cells (Supplementary Fig. 1d ).
We next evaluated the functionality of the TRPV1 channel in CD4 + T cells by the whole-cell patch-clamp technique. We used the prototypical TRPV1 agonist capsaicin 10 and recorded capsaicin-induced 1 0 5 6 VOLUME 15 NUMBER 11 NOVEMBER 2014 nature immunology A r t i c l e s currents in wild-type and Trpv1 −/− CD4 + T cells held at −85 mV (Fig. 2a) . In wild-type CD4 + T cells, the application of capsaicin rapidly induced a small inward current (1.7 ± 0.4 pA/pF (mean ± s.e.m.); n = 9 cells) that was desensitized with prolonged exposure to the agonist (Fig. 2a,b) . This desensitization was probably caused by the presence of Ca 2+ ions in the external solution, as demonstrated before in recordings of rat TRPV1 currents in HEK293 human embryonic kidney cells transfected to express TRPV1 (refs. 10,11) . In Trpv1 −/− CD4 + T cells, we recorded only an insignificant amount of inward current (0.4 ± 0.1 pA/pF (mean ± s.e.m.); n = 8 cells) in response to capsaicin (Fig. 2a,b) . Additionally, with the same recording conditions, we routinely recorded 2-to 10-nA capsaicin-gated currents from transformed human kidney (tSA201) cells with transient expression of rat TRPV1 (data not shown). To further confirm that the current observed in wild-type CD4 + T cells was indeed a TRPV1 current, we measured capsaicin-induced currents in the presence of SB366791, a specific TRPV1 antagonist 12 . SB366791 inhibited approximately 80% of the inward current observed in wild-type CD4 + T cells in response to capsaicin (untreated control, 2.0 ± 0.3 pA/pF (mean ± s.e.m.), n = 10 cells; SB366791 treated, 0.4 ± 0.1 pA/pF (mean ± s.e.m.), n = 13 cells) (Fig. 2a,c) . To better characterize the capsaicin-induced current in CD4 + T cells, we used a ramp-pulse protocol to measure the current-voltage relationship after the addition of capsaicin (Fig. 2d) . The currentvoltage relationship of the capsaicin-gated current confirmed the outward-rectification characteristic of the TRPV1 current reported for rat and human TRPV1 channels 10, 12 .
To further evaluate functionality of the TRPV1 channel in CD4 + T cells, we performed single-cell ratiometric Ca 2+ imaging and flow Figure 1 TRPV1 is expressed in CD4 + T cells. (a) Quantitative PCR analysis of transcripts encoding TRP proteins in splenic CD4 + T cells isolated from C57BL/6 (wild-type) mice; results normalized to those for the housekeeping gene Gapdh (encoding GAPDH) and presented relative to those for Trpm4 (known to be expressed in CD4 + T cells 27 ), set as 1. NS, not significant; *P < 0.05, **P < 0.001 and ***P < 0.0001 (one-way analysis of variance (ANOVA) with post-hoc Dunnett's test). (b) Electrophoresis of the products of quantitative PCR analysis of splenic CD4 + TCRβ + T cells isolated from wild-type (WT) and Trpv1 −/− mice and sorted by flow cytometry (purity, >98%): the Trpv1-specific product (top) migrates at the expected size of 188 base pairs (bp); Cd3d (encoding CD3δ) serves as a T cell marker; Gapdh (encoding glyceraldehyde phosphate dehydrogenase) serves as a loading control. (c) Flow cytometry of splenocytes isolated from wild-type mice, preincubated with a blocking peptide corresponding to TRPV1 (α-TRPV1 + peptide) or not (α-TRPV1) and then stained for CD4 and TCRβ (gated as CD4 + TCRβ + T cells) and with anti-TRPV1, or stained with the isotype-matched control antibody immunoglobulin G alone (IgG) (ctrl); numbers in plot indicate geometric mean fluorescence (GMF) of the staining intensity. or treated with 1 µM SB366791 (SB +) (n = 13) (c), assessed after treatment with capsaicin, calculated by normalization of peak current recorded at −85 mV to the capacitance of each cell. (d) Current-voltage relationship of the capsaicin-induced current in CD4 + T cells treated with 3 µM capsaicin and with a voltage ramp (−70 mV to +70 mV) delivered over 400 ms; results calculated by subtraction of current before the addition of capsaicin from current after that addition and normalization relative to the current at −70 mV (−19.2 ± 3.3 pA). (e) [Ca 2+ ] i in wild-type, Trpv1 −/− and Trpv1-TG splenic CD4 + CD25 − (naive) T cells loaded with the calcium indicator Fura-2 AM and treated with 10 µM capsaicin (gray bar) in the presence of 2 mM CaCl 2 (2 Ca; black bar), monitored by confocal imaging and presented as the ratio of Fura-2 emission at an excitation of 340 nm to that at 380 nm (340/380). (f) Quantification of Ca 2+ -influx profiles obtained as in e with 1 or 10 µM capsaicin. (g) Immunoblot analysis of TRPV1 and β-actin (loading control throughout) in total lysates of wild-type and Trpv1-TG splenic CD4 + T cells; doublets at ~95 kilodaltons (kDa) and 115 kDa correspond to the nonglycosylated and glycosylated forms of the TRPV1 channel 40 . Below lanes, densitometry analysis (band intensity relative to that of β-actin). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 (Fig. 2e,f) . In addition, we generated mice with transgenic expression of TRPV1 specifically in CD4 + T cells (Trpv1-TG mice) by crossing mice expressing Trpv1 from the ubiquitous Rosa26 locus 13 with mice expressing Cre recombinase from the T cell-specific Cd4 promoter. We found that capsaicin induced a substantial Ca 2+ influx in Trpv1-TG CD4 + T cells (Fig. 2e,f ) that overexpressed TRPV1 (Fig. 2g) . Capsaicin also induced a substantial Ca 2+ influx in Jurkat T cells, which was almost completely abolished after knockdown of TRPV1 mediated by short hairpin RNA (Supplementary Fig. 1e ).
Collectively, these findings indicated that the TRPV1 channel was functionally expressed on the plasma membrane of CD4 + T cells (TRPV1 CD4 ). (Fig. 3a,b) . We observed this defect in Trpv1 −/− CD4 + T cells independently of the extracellular calcium concentration tested or of the Ca 2+ flux-monitoring protocol used (for example, TCR stimulation before the addition of CaCl 2 or vice versa; Supplementary Fig. 2a-d) . In addition, Ca 2+ -titration experiments revealed that the TCR-induced Ca 2+ influx defect in Trpv1 −/− CD4 + T cells was 'rescued' by a 50% increase in the extracellular calcium concentration in the culture medium (Fig. 3c) . In accordance with the localization of TRPV1 CD4 at the plasma membrane (Fig. 1d,e and Supplementary Fig. 1d ), the Ca 2+ efflux from intracellular stores was similar in wild-type and Trpv1 −/− CD4 + T cells after stimulation of the TCR (Supplementary Fig. 2e ). The TCR-induced Ca 2+ influx was significantly more sustained in Trpv1-TG CD4 + T cells than in wild-type cells (Fig. 3a,b and Supplementary Fig. 2f ). However, we observed no difference among wild-type, Trpv1 −/− and Trpv1-TG CD4 + T cells in Ca 2+ influx following stimulation with the Ca 2+ ionophore ionomycin (Fig. 3a,b and Supplementary Fig. 2g,h ) or with the sarcoplasmic reticulum Ca 2+ -ATPase pump inhibitor thapsigargin (Fig. 3d,e and Supplementary Fig. 2i ), which bypass proximal TCR signaling and induce activation of Ca 2+ release-activated Ca 2+ channels and store-operated Ca 2+ entry 14 . Since TRPV3 shares 40-50% homology with TRPV1 and can form heteromultimers with that channel 9,15 , we also analyzed the Ca 2+ -influx profile of spleen CD4 + T cells isolated from Trpv3 −/− mice. However, in contrast to Ca 2+ influx in Trpv1 −/− CD4 + T cells, we found normal Ca 2+ influx in these cells upon stimulation of the TCR (Supplementary Fig. 2j ).
We further confirmed the specific contribution of TRPV1 to TCR-induced Ca 2+ currents by whole-cell patch-clamp experiments. Crosslinking of TCRs produced significantly smaller inward currents in Trpv1 −/− CD4 + T cells held at −85 mV (4.1 ± 0.6 pA/ pF (mean ± s.e.m.); n = 9 cells) than in wild-type cells under the same experimental conditions (12.3 ± 3.3 pA/pF (mean ± s.e.m.), n = 7 cells) (Fig. 3f,g ). Finally, pretreatment of wild-type CD4 + T cells with either of two different TRPV1 antagonists, BCTC 16 ( Fig. 3h,i) or I-RTX 17 ( Supplementary Fig. 2k ), decreased the Ca 2+ influx induced by TCR stimulation to a level similar to that in Trpv1 −/− CD4 + T cells and did so in a concentration-dependent way. Collectively, these results suggested that TRPV1 CD4 acted as a non-store-operated Ca 2+ channel and contributed to TCRinduced Ca 2+ influx. A r t i c l e s TRPV1 CD4 is part of the TCR signaling cascade We then investigated how TRPV1 CD4 was activated upon stimulation of the TCR and assessed its effect on TCR signaling. We first compared the subcellular localization of TRPV1 in resting and activated CD4 + T cells by confocal microscopy. We found that under resting conditions, TRPV1 localized together with components of the TCR complex, such as the coreceptor CD4 (Fig. 1d,e) and the Src-family tyrosine kinase Lck (Fig. 4a) . In addition, Lck and TRPV1 were rapidly recruited to TCR clusters after ligation of the TCR (Fig. 4a) . Since formation of the cap structure is known to be dependent on tyrosine phosphorylation 18, 19 , we investigated whether TRPV1 clustering was dependent on a similar mechanism. Indeed, we found that PP2, an inhibitor of the Src family of tyrosine kinases 20 , inhibited capping of Lck and TRPV1 (Fig. 4a) .
Because the phosphorylation of TRP channels regulates their channel activity [21] [22] [23] , we investigated whether engagement of the TCR induced tyrosine phosphorylation of TRPV1 CD4 . To address the possible role of Lck in this system, we examined the tyrosine-phosphorylation status of endogenous TRPV1 immunoprecipitated from wild-type Jurkat T cells (clone E6.1) and a derivative mutant of Jurkat T cells that lack Lck expression (J.CaM1.6) 24 . Stimulation of the TCR induced tyrosine-phosphorylation of TRPV1 in the parental wild-type E6.1 cell line but not in the mutant, Lck-deficient J.CaM1.6 cells (Fig. 4b ). In accordance with published studies that have demonstrated an essential role for tyrosine kinases of the Src family in the activation of TRPV1 channels [21] [22] [23] , we found that TRPV1 CD4 -mediated Ca 2+ influx was almost completely abolished in the absence of Lck (Fig. 4c) . Collectively, these results suggested that TRPV1 is part of the proximal TCR signaling cascade and that tyrosine phosphorylation by Lck is a possible gating mechanism for TRPV1 CD4 after stimulation of the TCR.
We next evaluated the effect of TRPV1 deficiency on TCR signaling. We found no difference in phosphorylation of the TCR-proximal signaling components Zap70, Lat (Fig. 4d) and PLC-γ1 (Fig. 4e) , a slight difference in phosphorylation of the kinases Erk1/2 and p38, and less activation of the kinase Jnk (Fig. 4f) in Trpv1 −/− CD4 + T cells relative to that in wild-type CD4 + T cells. Consistent with their decreased TCR-induced Ca 2+ influx, Trpv1 −/− CD4 + T cells failed to sustain localization of NFAT-1 to the nucleus ( Fig. 4g) and displayed reduced activation of NF-κB (Fig. 4h) upon stimulation of the TCR. 
A r t i c l e s
Thus, TRPV1 CD4 seemed to be dispensable for proximal TCR signaling but was required for the proper transduction of distal TCR signaling events.
TRPV1 CD4 contributes to TCR-induced cytokine production
We reasoned that the altered TCR signaling in Trpv1 −/− CD4 + T cells would affect their subsequent cytokine production. We observed that Trpv1 −/− CD4 + T cells produced lower concentrations of various cytokines (interferon-γ (IFN-γ), interleukin 17A (IL-17A), IL-2, IL-10, IL-4 and tumor-necrosis factor (TNF)) after stimulation with anti-CD3 and antibody to the coreceptor CD28 (anti-CD28) than did wild-type cells (Fig. 5a) . We observed the opposite phenotype for Trpv1-TG CD4 + T cells (Supplementary Fig. 3a) . The diminished cytokine production by Trpv1 −/− CD4 + T cells was not explained by increased apoptosis or a lower proliferative response of these cells (Supplementary Fig. 4) . Moreover, TCR-independent activation of Trpv1 −/− and wild-type CD4 + T cells with the phorbol ester PMA and ionomycin resulted in similar secretion of IFN-γ and IL-2 (Fig. 5a) . Using IL-2 as a 'readout' , we found that its diminished production by Trpv1 −/− CD4 + T cells was 'rescued' by an increase in the extracellular calcium concentration in the culture medium (Fig. 5b) . These data suggested that the diminished cytokine production in Trpv1 −/− CD4 + T cells was probably due to the decreased TCR-induced Ca 2+ influx observed in these cells ( Fig. 3 and Supplementary Fig. 2 ). In addition, in an antigen-specific model (OT-II cells, which have transgenic expression of an ovalbumin (OVA)-specific TCR), we found that Trpv1 −/− OT-II CD4 + T cells stimulated with OVA-loaded wild-type dendritic cells (DCs) had lower production of IFN-γ, IL-17A and IL-2 than did control (Trpv1 +/+ ) OT-II cells under the same stimulatory conditions ( Fig. 5c and Supplementary Fig. 3b) .
To further confirm the contribution of TRPV1 CD4 -induced signaling to cytokine production, we treated wild-type CD4 + T cells with the TRPV1 antagonist BCTC. BCTC decreased the release of cytokines from CD4 + T cells in a concentration-dependent way upon stimulation with anti-CD3 plus anti-CD28 (Fig. 5d) . The observed decrease in cytokine production was not due to an increase in the apoptosis of CD4 + T cells (Fig. 5e) . BCTC also significantly diminished cytokine production by OT-II CD4 + T cells upon stimulation with OVA-loaded DCs (Fig. 5f ). Together these results suggested a cell-intrinsic role for TRPV1 CD4 in promoting TCR-induced cytokine production.
TRPV1 inhibition decreases human CD4 + T cell activation
To explore the relevance of the data generated in the mouse to the human system, we determined the effect of pharmacological inhibition of TRPV1 on the activation profile of primary CD4 + T cells enriched from the peripheral blood of healthy donors. We stimulated the cells with anti-CD3 plus anti-CD28 in the presence or absence of the TRPV1 antagonist SB366791. We analyzed upregulation of the surface expression of activation markers (i.e., CD25 and HLA-DR) 48 h later and found that SB366791 decreased their expression in a concentration-dependent way (Fig. 6a,b) . Consistent with results obtained with the mouse npg system, inhibition of TRPV1 also decreased IL-2 production (Fig. 6c) . Notably, we observed this effect even at very low concentrations of the antagonist SB366791 (≥0.01 µM), and it was not associated with increased apoptosis of CD4 + T cells (Fig. 6d) . To confirm those findings, we knocked down TRPV1 in primary human CD4 + T cells through the use of small interfering RNA (siRNA). Similar to pharmacological inhibition of TRPV1, knockdown of TRPV1 decreased the expression of CD25 and HLA-DR (Fig. 6e,f) and the production of IL-2 (Fig. 6g,h ) upon stimulation with anti-CD3 plus anti-CD28. Collectively, these data indicated the TRPV1 channel contributed to the activation of human CD4 + T cells.
TRPV1 CD4 regulates proinflammatory CD4 + T cell responses
To analyze the contribution of TRPV1-induced signaling to CD4 + T cell responses in vivo, we applied two different models of CD4 + T cell-mediated colitis. We first used the Il10 −/− model 25 and compared the severity of colitis in Il10 −/− mice and Il10 −/− Trpv1 −/− mice. Il10 −/− mice lost more weight than Il10 −/− Trpv1 −/− mice did after the induction and synchronization of colitis by oral treatment with the nonselective cyclooxygenase inhibitor piroxicam 26 (Fig. 7a) . Histological analysis of the colon confirmed that Il10 −/− mice developed severe inflammation with epithelial hyperproliferation, crypt loss and cellular infiltration in the mucosa and submucosa, whereas we observed significantly lower inflammatory response in Il10 −/− Trpv1 −/− mice (Fig. 7b,c) . In addition, Il10 −/− mice treated with the TRPV1 antagonist SB366791 showed attenuated colonic inflammation and T cell-derived production of inflammatory cytokines compared with that of Il10 −/− mice treated with vehicle ( Supplementary Fig. 5) .
To confirm the cell-intrinsic role of TRPV1 CD4 in intestinal inflammation, we transferred wild-type or Trpv1 −/− naive (CD4 + CD45RB hi CD25 − ) T cells into recipient mice deficient in recombination-activating gene 1 (Rag1 −/− mice) and assessed their ability to elicit colitis 25 . We used Rag1 −/− recipients of wild-type naive CD4 + T cells transferred together with regulatory T cells (T reg cells) (CD4 + CD45RB lo CD25 + ) as a control. The adoptive transfer of wildtype naive CD4 + T cells alone induced severe colitis in the recipients, as reflected by significant body weight loss, high disease activity index and histological signs of severe colitis (Fig. 7d-g and Supplementary  Fig. 6a,b) . We did not observe this after the transfer of Trpv1 −/− naive CD4 + T cells (Fig. 7d-g and Supplementary Fig. 6a,b) . Massive cellular infiltration coincident with severe crypt loss was evident in the colons of Rag1 −/− mice given transfer of wild-type naive CD4 + T cells, but not in the colons of those given transfer of Trpv1 −/− naive CD4 + T cells (Supplementary Fig. 6c) . To quantify the inflammatory cytokines produced in the colonic mucosa of these mice, we cultured colonic explants ex vivo. The colonic explants of Rag1 −/− mice given transfer of wild-type naive CD4 + T cells released more IFN-γ, IL-17A and TNF than did those from recipients of Trpv1 −/− naive CD4 + T cells (Fig. 7h) . The abundance of mRNA encoding several proinflammatory cytokines (Ifng, Il17a, Il22, Tnf and Il1b) and chemokines (Cxcl1, Cxcl9, Cxcl10, Ccl2 and Ccl13) was also lower in colon homogenates from recipients of Trpv1 −/− CD4 + T cells than in those of recipients of wild-type CD4 + T cells (Supplementary Fig. 6d ).
The transferred Trpv1 −/− CD4 + T cells secreted significantly lower amounts of proinflammatory cytokines (IFN-γ, IL-17A and TNF) than did the transferred wild-type CD4 + T cells (Fig. 7i) . Moreover, the number of CD4 + T cells producing IFN-γ, IL-17A or IL-10 was also much lower in the spleen, mesenteric lymph nodes and lamina propria of the recipients of Trpv1 −/− naive CD4 + T cells than in those of the recipients of wild-type naive CD4 + T cells ( Supplementary  Fig. 7 ). This suggested that the decreased colitogenicity of Trpv1 −/− naive CD4 + T cells was possibly due to defective activation and differentiation in situ. In line with this hypothesis, we found that Trpv1 −/− OT-II naive CD4 + T cells were less able to differentiate into effector cells of the T H 1, T H 2 and T H 17 subsets of helper T cells in vitro than were control (Trpv1 +/+ ) OT-II naive cells (Supplementary Fig. 8 ).
To analyze the potential contribution of TRPV1 to other cell types in the recipients, we compared the colitis induced by the transfer of wildtype naive CD4 + T cells into Rag1 −/− mice with that induced in Rag1 −/− Trpv1 −/− recipients. We found that Rag1 −/− and Rag1 −/− Trpv1 −/− recipients developed similar body weight loss and colonic inflammation and displayed similar proinflammatory CD4 + T cell responses (Fig. 8) . Finally, in line with their enhanced activation profile in vitro (Supplementary Fig. 3a) , Trpv1-TG naive CD4 + T cells induced exacerbated colitis after transfer into Rag1 −/− recipients ( Supplementary  Fig. 9 ). Together these results demonstrated a cell-intrinsic role of TRPV1 CD4 in promoting the activation and inflammatory responses of T cells (proposed model for the regulation of T cell activation by TRPV1, Supplementary Fig. 10 ).
DISCUSSION
While Ca 2+ release-activated Ca 2+ channels have been described as the major source for the entry of Ca 2+ into T cells 1, 3 , several additional families of channels expressed on the plasma membrane of T cells may have important roles in this process, including voltage-gated Ca 2+ channels and TRP channels 2, 5, 6 . In particular, the contribution of TRP channels to this process is not well defined. TRP channels may decrease Ca 2+ influx in T cells (for example, TRPM4) 27 or increase such influx (for example, TRPC3) 7, 28 , and it is as yet unclear whether they directly affect TCR signaling and T cell activation.
In the present study, we found that the TRPV1 channel was functionally expressed in CD4 + T cells (TRPV1 CD4 ) and reported a previously unknown function for TRPV1 beyond its well-recognized role as a pain receptor 10, 29 . Our results indicated an essential role for TRPV1 CD4 in the activation and the acquisition of inflammatory properties by CD4 + T cells. TRPV1 expression has been reported in peripheral blood lymphocytes in rats 30 and in humans 7, [31] [32] [33] [34] , but the functionality of the TRPV1 channel was not assessed and it remained unknown whether TRPV1 has a role in the activation and function of T cells. In this study, we demonstrated that TRPV1 was constitutively expressed in mouse and human CD4 + T cells as well as in the Jurkat human leukemic T cell line. By whole-cell patch clamp, we demonstrated the functionality of the TRPV1 channel at the plasma membrane and recorded capsaicin-induced currents in wild-type CD4 + T cells but not in Trpv1 −/− CD4 + T cells. The smaller TRPV1 current observed in CD4 + T cells than that reported before in sensory neurons or in cells with heterologous overexpression of TRPV1 might account for the following cell-intrinsic factors: lower channel and showed that it contributed to TCR-induced Ca 2+ influx in a manner independent of store-operated Ca 2+ entry. We also confirmed the contribution of TRPV1 to TCR-induced Ca 2+ currents by whole-cell patch clamp and found that crosslinking of TCRs produced significantly smaller inward currents in Trpv1 −/− CD4 + T cells than in wild-type cells.
Our results suggest that TRPV1 is a component of the TCR signaling complex, since it is rapidly recruited to TCR clusters upon TCR stimulation in a Src-dependent manner. Through the use of a Jurkat cell clone that lacks expression of the Src-family kinase Lck 24 , we showed that Lck rapidly tyrosine-phosphorylated TRPV1 after stimulation via the TCR and regulated TRPV1 CD4 channel activity. Tyrosine phosphorylation by Src kinase has been shown to be essential for the activation of TRPV1 channels in other cell types. Indeed, capsaicin-induced currents in dorsal root ganglion neurons are blocked by the Src-family kinase inhibitor PP2 and are enhanced by the tyrosine phosphatase inhibitor sodium orthovanadate. PP2 also abolishes currents in HEK293 cells transfected to express rat TRPV1, whereas cotransfection of cells to express TRPV1 with an activated Src kinase (v-Src) results in fivefold increase in capsaicin-induced currents 21 . Finally, in cells transfected to express a dominant-negative non-receptor (c-Src) tyrosine kinase, capsaicin-induced currents are considerably diminished 21, 23 . This mode of activation by Src-family kinases is not restricted to TRPV1 and has also been shown for other members of the TRP family 22 . Our findings are therefore consistent with the reported protein-protein interaction of TRPV1 and Src and emphasize the role of Src-family kinases in regulating the activity of TRPV1 channels [21] [22] [23] . Tyrosine-phosphorylation by Lck is therefore a possible gating mechanism for TRPV1 CD4 after stimulation of the TCR.
Analysis of TCR signaling in wild-type and Trpv1 −/− CD4 + T cells revealed diminished activation of the p38 and Jnk pathways and less translocation of NF-κB to the nucleus in Trpv1 −/− CD4 + T cells. In line with their decreased TCR-induced Ca 2+ influx, Trpv1 −/− CD4 + T cells also failed to maintain localization of NFAT-1 to the nucleus after stimulation via the TCR. Consequently, Trpv1 −/− CD4 + T cells displayed a significantly diminished cytokine-production profile after either antigen-specific stimulation (OVA-loaded DCs) or nonspecific stimulation (with anti-CD3 plus anti-CD28). Collectively, these data indicated that TRPV1 was necessary for proper TCR-induced signaling and cytokine production but was dispensable for CD4 + T cell proliferation under our experimental conditions. Consistent with our in vitro data, we found a role for TRPV1 CD4 in T cell inflammatory responses in vivo in two different models of inflammatory bowel disease. Il10 −/− Trpv1 −/− mice and Il10 −/− mice treated with a TRPV1 antagonist had less colonic inflammation than did untreated Il10 −/− control mice. In addition, Trpv1 −/− naive CD4 + T cells had an impaired ability to elicit colitis when transferred into Rag1 −/− recipients. As the activation of TRPV1 in sensory afferents contributes to neurogenic inflammation, which might affect the severity of colitis 38 , we compared the colitis induced by the transfer of wild-type naive CD4 + T cells into Rag1 −/− mice with that induced in Rag1 −/− Trpv1 −/− recipient mice. Genetic deletion of TRPV1 in donor CD4 + T cells determined the severity of colonic inflammation in this model, but genetic deletion of TRPV1 in other cells of the recipients did not. The T cell-intrinsic role of TRPV1 was further demonstrated by the enhanced activation profile and proinflammatory properties of Trpv1-TG CD4 + T cells.
Finally, our results indicated that inhibition of TRPV1 CD4 in mouse and human CD4 + T cells with TRPV1 antagonists or with TRPV1-specific siRNA recapitulated the phenotype of Trpv1 −/− CD4 + T cells. As TRPV1 functions as a nociceptor (i.e., pain receptor) in sensory neurons 29 , TRPV1 antagonists were developed as analgesic agents 39 . The immunomodulatory properties of TRPV1 antagonists identified in our study suggest that their application might be beneficial in patients with CD4 + T cell-mediated immunopathologies such as inflammatory bowel disease.
METHODS
Methods and any associated references are available in the online version of the paper. 
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Reagents and antibodies.
For immunoblot analysis, we used the following antibodies: antibody to phosphorylated Erk1/2 (D13.14.4E), antibody to phosphorylated p38 (D3F9), antibody to phosphorylated Jnk (81E11), antiErk1/2 (137F5), anti-p38 (9212), anti-Jnk (9252), antibody to Zap70 phosphorylated at Tyr319 (2701) and antibody to PLC-γ1 phosphorylated at Tyr783 (2821; all from Cell Signaling Technology); antibody to Lat phosphorylated at Tyr191 (07-278) and antibody to phosphorylated tyrosine (4G-10; both from Millipore); anti-CD3ε (M-20; sc-1127), anti-Lck (2102; sc-13) and anti-TRPV1 (P-19; sc-12498; all from Santa Cruz Biotechnology); anti-TRPV1 (ACC-030; Alomone); monoclonal anti-NFAT1 (ab2722; Abcam); and anti-β-actin (AC-74; Sigma). For immunofluorescence studies, we used anti-TRPV1 (sc-12498; Santa Cruz Biotechnology), anti-Lck (sc-13; Santa Cruz Biotechnology), anti-CD4 (GK1.5; eBioscience), anti-CD45 (30-F11; BD Biosciences) and anti-claudin-3 (RB-9251; Thermo Scientific). For T cell stimulation, we used monoclonal anti-mouse CD3ε (145-2c11) and anti-mouse CD28 (PV-1; both from BioXcell), and monoclonal anti-human CD3ε (UCHT1) and anti-human CD28 (CD28.2; both from eBioscience). Other reagents included the following: PMA (phorbol 12-myristate 13-acetate), ionomycin, thapsigargin and phytohemagglutinin (all from Sigma); PP2 (Cayman Chemical); BCTC (N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide) and I-RTX (iodo-resiniferatoxin) (Tocris); SB366791 (Enzo Life Sciences); an annexin-V and 7-amino-actinomycin D (7-AAD) apoptosis-detection kit (BD Biosciences); and CFSE (carboxyfluorescein diacetate succinimidyl ester), Indo-1 AM, and Fura-2 AM (Invitrogen).
Isolation of mRNA and quantitative PCR. RNA was isolated with an RNeasy Mini Kit according to the manufacturer's protocol (Qiagen). 1 µg of RNA sample was used for reverse transcription and synthesis of cDNA with qScript cDNA superMix (Quanta Biosciences). Quantitative real-time PCR was performed on an AB7300 (Applied Bisosytems) with PerfeCTa SYBR Green FastMix (Quanta Biosciences). Primers for specific target genes were designed on the basis of their reported sequences and were synthesized by IDT Technologies (sequences, Supplementary Tables 1 and 2) . The expression of genes encoding several TRP channels in mouse CD4 + T cells was compared after verification that amplification efficiencies for the different target genes were similar. For analysis of TRPV1 expression, quantitative PCR products were separated by electrophoresis through a 2% agarose gel, followed by staining with SYBR Safe DNA (Invitrogen) for further confirmation of the specificity of the primers used.
Mice. Six-to ten-week-old mice were used for all experimental procedures. Mice were bred for more than 6 months and were genotyped before they were used in any experiments. All experimental procedures were conducted in accordance with institutional guidelines for animal care and use of the University of California, San Diego.
Isolation and stimulation of CD4 + T cells. Mouse CD4 + T cells were isolated from the spleen or mesenteric lymph nodes with a CD4 + T cell negative selection kit (19752; StemCell). Purity of the enriched populations was controlled by staining with anti-CD4 (GK1.5; eBioscience) and anti-TCRβ (H57-597; eBioscience) by flow cytometry and was typically >94% for CD4 + T cells derived from the spleen and >97% for CD4 + T cells derived from the mesenteric lymph nodes. For ELISA, CD4 + T cells were stimulated with 10 µg/ml plate-bound anti-CD3 (145-2c11; BioXcell) and 1 µg/ml soluble anti-CD28 (PV-1; BioXcell) in RPMI-1640 medium supplemented with 10% heat-inactivated FCS, 2 mM l-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Culture supernatants were collected at 24 h and 48 h for analysis of cytokine production (ELISA kits; eBioscience). For signaling experiments, CD4 + T cells were stimulated for various times (for example, 0, 15, 30 or 60 min) with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 (both soluble; antibodies identified above). Splenic CD4 + T cells from OT-II or Trpv1 −/− OT-II mice were isolated as described above. Bone marrow-derived DCs were cultured and harvested as described 42 were grown in complete RPMI-1640 medium (supplemented with 5% heat-inactivated FCS, 2 mM l-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin) and were stimulated for the appropriate time with soluble antibody to human CD3 (2.5 µg/ml; OKT3; BioLegend) and antibody to human CD28 (1 µg/ml; CD28.2; eBioscience).
In vitro T cell differentiation. CD4 + CD25 − (naive) T cells were isolated from the spleen of wild-type OT-II or Trpv1 −/− OT-II mice, and bone marrowderived DCs were loaded for 24 h at 37 °C with OVA peptide (10 µg/ml; amino acids 323-339) and were γ-irradiated (30 Gy from a 137 Cs source). Those cells were cultured together (at a density of 1 × 10 6 T cells per well and 5 × 10 5 DCs per well) in flat-bottomed 24-well plates in complete RPMI medium (unless indicated otherwise) in the presence of the following: for T H 1 differentiation, recombinant mouse IL-12 (10 ng/ml; eBioscience) and neutralizing anti-IL-4 (10 µg/ml; BVD6-24G2; BioXcell); for T H 2 differentiation, recombinant mouse IL-4 (10 ng/ml), neutralizing anti-IFN-γ (10 µg/ml; XMG1.2; BioXcell) and neutralizing anti-IL-12 (10 µg/ml; R1-5D9; BioXcell); for T H 17 differentiation, recombinant mouse IL-6 (20 ng/ml) and TGF-β (4 ng/ml; both from eBioscience), plus neutralizing anti-IFN-γ (10 µg/ml; XMG1.2; BioXcell) and anti-IL-4 (10 µg/ml; BVD6-24G2; BioXcell) in complete IMDM; and for T reg cell differentiation, recombinant mouse TGF-β (10 ng/ml; eBioscience) and IL-2 (20 ng/ml; eBioscience). At day 2, recombinant mouse IL-2 (10 ng/ml) was added to the T H 1 and T H 2 cultures. After 4 d, CD4 + T cells were recovered and then were restimulated for 5 h or not with 10 µg/ml plate-bound anti-CD3 and 1 µg/ml soluble anti-CD28 (antibodies identified above) in the presence of GolgiStop (BD Biosciences). Intracellular cytokines were measured with anti-IFN-γ (XMG1.2), anti-IL-4 (11B11), anti-IL-17A (eBio17B7) and anti-IL-10 (JES5-16E3) according to the manufacturer's instructions (eBioscience).
Knockdown of TRPV1. Primary human CD4 + T cell clones or freshly isolated PBMCs were transfected with 400 nM TRPV1-specific siRNA (a pool of three different siRNA duplexes; sc-36826; Santa Cruz Biotechnology) or control siRNA (Non-Targeting siRNA #1; Dharmacon) at a density of 5 × 10 6 cells per 100 µl human T cell nucleofector solution (VPA-1002; Lonza) with the Amaxa Nucleofector II device (program U-014; Lonza). After nucleofection, cells were immediately transferred into prewarmed complete RPMI-1640 and were cultured in a 24-well plate at 37 °C in a 5% CO2 humidified incubator. Six hours after transfection, cells were stimulated for a further 42 h with antibody to human CD3 and antibody to human CD28 (identified above; both 1 µg/ml, soluble). TRPV1-knockdown efficiency in cells was then analyzed (by flow cytometry and immunoblot analysis), as was upregulation of the expression of the surface activation markers CD25 and HLA-DR (by flow cytometry) and cytokine IL-2 production (by ELISA). 45, 46 . Cells were suspended at a density of 2.5 × 10 6 cells per ml in 2% FBS in PBS and were prelabeled for 10 min at 37 °C with 40 nM CFSE (carboxyfluorescein diacetate succinimidyl ester; Invitrogen) or were mock-treated and mixed in equal proportions (for example, wild-type cells (CFSE) plus Trpv1 −/− cells (mock)). In some experiments, the CFSEand mock-treated pairs were reversed to ensure that the CFSE staining did not alter the results. Cells were washed, then were resuspended at a density of 5 × 10 6 cells per ml in2% FBS in PBS and were incubated for 30 min at 37 °C in 5% CO 2 with 2 µM Indo-1 AM (Molecular Probes). Cells were then washed, stained with allophycocyanin-anti-CD4 (GK1.5; eBioscience) and resuspended a density of 1 × 10 6 cells per ml in complete RPMI medium. Finally, cells were transferred to calcium-free medium (Ca 2+ -and Mg 2+ -free Hank's balanced-salt solution supplemented with 2% FCS and 1 mM EGTA) just before the beginning of the acquisition. Cells were preincubated or not for 5 min at 37 °C with various concentrations of TRPV1 antagonists (BCTC or I-RTX) or with vehicle (0.1% DMSO) and were stimulated at 37 °C with 1 or 10 µM capsaicin, 10 µg/ml anti-CD3 and 1 µg/ml anti-CD28 (antibodies identified above) or, alternatively, with 500 nM of ionomycin or 1 µM thapsigargin. , and were left unstimulated or stimulated for 5 min at 37 °C with anti-CD3 as described above. Cells were stained for TRPV1 as described above, or for 1 h at 4 °C with rabbit antibody to Lck (sc-13; Santa Cruz Biotechnology) and for 30 min at 4 °C with the secondary antibody Alexa Fluor 647-anti-rabbit (A21244; Invitrogen). All primary and secondary antibodies were used at a dilution of 1:100 unless indicated otherwise. One cytospin preparation served as a negative control staining with the control antibody IgG or the secondary antibodies only. Cells were finally stained for 10 min at room temperature with Hoechst 33342 (50 ng/ml; Invitrogen) and rinsed with deionized water and slides were mounted in ProLong Gold antifade reagent (Invitrogen). The fluorescence images were acquired using a 100× oil-immersion objective on a confocal laser-scanning microscope (Olympus IX81) with Fluoview software. Colocalization was assessed with Velocity software.
Electrophysiological assay. Whole-cell patch-clamp recording and analysis were carried out on an Axopatch 200B amplifier with Digidata1322A interface and pClamp9 software (Axon Instruments). Patch electrodes were pulled from thin-walled borosilicate glass (World Precision Instruments) on a horizontal micropipette puller (Sutter Instruments). Electrodes had a resistance of 8-20 MΩ when filled with intracellular solution. Analog capacity compensation and series resistance compensation were used during whole-cell recordings. For single pulse recordings, spleen CD4 + T cells were held at −85 mV and 16 µM capsaicin was introduced via a gravity-fed perfusion system into the recording chamber with a TC344B heater controller and an SH-27B inline heater (Warner instruments). For experiments performed in the presence of SB366791, cells were pretreated for 30 min in external solution containing 1 µM SB366791, and currents were then recorded in the presence of both capsaicin (16 µM) and SB366791 (1 µM). For TCR stimulation, cells were first pretreated for 20 min at 4 °C with biotinylated anti-CD3 (20 µg/ml; 145-2C11; eBioscience), and then they were activated by the addition of streptavidin (10 µg/ml) in the external solution and were held at −85 mV. Data were sampled at 10 kHz and filtered at 5 kHz, and whole-cell recordings were performed at 35 °C. The extracellular solution contained 144 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 10 mM glucose and 10 mM HEPES and was adjusted to a pH of 7.4 with NaOH. The intracellular solution used in the pipettes contained 126 mM K-gluconate, 10 mM KCl, 5 mM EGTA, 4 mM MgATP and 10 mM HEPES and was adjusted to a pH of 7.4 with KOH. For analysis of currentvoltage relationships, the external solution contained 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , 5 mM EGTA, 10 mM HEPES and 10 mM glucose and was adjusted to a pH of 7.2 with NaOH. The internal solution contained 136 mM CsCl, 5 mM EGTA, 10 mM HEPES and 4 mM MgATP and was adjusted to a pH of 7.4 with NaOH. Liquid junction potential was calculated at +15 mV and was corrected offline.
Electrophoretic mobility-shift assay, immunoprecipitation and immunoblot analysis. For assessment of translocation of NF-κB and NFAT-1 to the nucleus in wild-type and Trpv1 −/− spleen CD4 + T cells, cytoplasmic cell extracts were made by lysis via incubation for 5 min on ice in hypotonic lysis buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA and complete protease inhibitors (Roche)). After collection of the cytoplasmic extracts, cell pellets were lysed for 5 min on ice in nuclear extract buffer B (20 mM HEPES, pH 7.9, 420 mM NaCl, 1 mM EDTA and protease inhibitors). Translocation of activated NF-κB into the nucleus was measured by electrophoretic mobility-shift assay with consensus NF-κB oligonucleotides (Santa Cruz Biotechnologies) as described 42 . Translocation of NFAT-1 was analyzed in the nuclear fractions by immunoblot with mouse monoclonal anti-NFAT-1 (ab2722; Abcam). The phosphorylation of Zap70, Lat, Erk1/2, p38 and Jnk was assessed in the cytosolic fraction with antibodies specific for the phosphorylated and total forms of these proteins (antibodies identified above).
The protein concentration was determined with a protein-quantification kit (Bio-Rad). Protein samples (10 µg/lane) were separated by SDS PAGE (4-12% acrylamide NuPAGE Novex bis-Tris precast gels; Life Technologies) and then were transferred to PVDF membranes (Millipore). Nonspecific binding in the blots was blocked by incubation for 45 min at room temperature in 5% BSA and 0.3% Tween-20 in PBS, and blots were incubated overnight at 4 °C with primary antibodies (identified above; all at a dilution of 1:1,000). The blots were washed and then were incubated for 45 min at room temperature with their corresponding horseradish peroxidase-conjugated secondary antibody (705-035-003, 115-035-174 and 711-065-152; Jackson ImmunoResearch Laboratories; each at a dilution of 1:5,000 to 1:10,000) and were developed in ECL solution (Pierce). Image J software was used for quantification of immunoblot analysis results by band densitometry. For measurement of TRPV1 expression by immunoblot analysis, resting mouse and human primary CD4 + T cells, Jurkat T cells, and control or rat TRPV1-overexpressing Chinese hamster ovary cells, were lysed with RIPA buffer (Teknova) supplemented with protease inhibitors (Roche), followed by immunoblot analysis as described above with anti-TRPV1 (sc-12498 (Santa Cruz) at a dilution of 1:1,000, or ACC-030 (Alomone) at a dilution of 1:200). For analysis of the tyrosine phosphorylation of TRPV1, wild-type and Lck −/− Jurkat T cells were left resting or were stimulated with 2.5 µg/ml anti-human CD3 plus 1 µg/ml anti-human CD28 (antibodies identified above) and then were lysed with RIPA buffer supplemented with protease inhibitors (Roche), then proteins were immunoprecipitated from cleared lysates by incubation overnight at 4 °C with goat anti-TRPV1 (sc-12498; Santa Cruz Biotechnology) coupled to protein A magnetic beads (New England Biolabs). Normal goat IgG was used as negative control (sc-2028; Santa Cruz Biotechnology). Then the immunoprecipitates were washed three times with lysis buffer and separated by SDS-PAGE. Blots were probed with antibodies to phosphorylated tyrosine, anti-TRPV1 and anti-Lck as described above (antibodies identified above).
Il10 −/− model of colitis. 8-to 10-week-old sex-and age-matched Il10 −/− or Il10 −/− Trpv1 −/− mice were randomly assigned to experimental groups. To overcome the variability in severity and onset of the disease in this model, colitis was induced by treatment with the nonsteroidal anti-inflammatory drug piroxicam 26 (Sigma). Mice were fed normal chow for 14 consecutive days, without mixture or mixed with piroxicam (50 mg per 250 g chow for the first week and 70 mg per 250 g chow for the second week). In some experiments, Il10 −/− mice were treated daily with SB366791 (3 mg per kg body weight; given intraperitoneally) or with vehicle (10% DMSO and 90% saline) starting 3 d before and daily during the 14 d of the colitis induction by piroxicam. Wasting disease in the groups was monitored periodically and mice were killed at day 30 for analysis.
T cell-adoptive transfer model of colitis. Splenic naive CD4 + T cells isolated from wild-type, Trpv1 −/− or Trpv1-TG donor mice were adoptively transferred into Rag1 −/− or Rag1 −/− Trpv1 −/− recipients as described 47, 48 . Samples were enriched for CD4 + T cells by immunomagnetic negative selection, then cells were stained with allophycocyanin-anti-CD4 Alexa Fluor 488-anti-CD25 and phycoerythrin-anti-CD45RB (antibodies identified above) and were sorted into populations of naive CD4 + CD45RB hi CD25 − cells and regulatory CD4 + CD45RB lo CD25 + cells (usual purity, >98%) with a BD FACSAria II flow cytometer. 8-to 10-week-old sex-and age-matched Rag1 −/− or Rag1 −/− Trpv1 −/− recipients were reconstituted by intraperitoneal injection of 3 × 10 5 naive CD4 + T cells from wild-type, Trpv1 −/− or Trpv1-TG sex-matched donor mice. For cotransfer experiments, 1.5 × 10 5 T reg cells from wild-type mice were injected together with the naive CD4 + T cells. After reconstitution, mice were monitored weekly for signs of intestinal inflammation, such as weight loss and diarrhea. The disease activity index (the combined score of weight loss and bleeding) was determined as described 47, 48 . Diseased mice were killed for analysis.
Isolation of lamina propria lymphocytes. Lamina propria lymphocytes were isolated as described 47 . Colons were washed with PBS and cut into small pieces (~1-2 mm in width). Tissue pieces were digested twice for 30 min at 37 °C, under rotation, with PBS containing 0.5 mg/ml of collagenase IV and 0.5 mg/ml of DNase I (both from Sigma). Cell suspensions containing lamina
